JPH029040B2 - - Google Patents

Info

Publication number
JPH029040B2
JPH029040B2 JP60000744A JP74485A JPH029040B2 JP H029040 B2 JPH029040 B2 JP H029040B2 JP 60000744 A JP60000744 A JP 60000744A JP 74485 A JP74485 A JP 74485A JP H029040 B2 JPH029040 B2 JP H029040B2
Authority
JP
Japan
Prior art keywords
stearate
erythromycin
acetylerythromycin
ethyl acetate
ester
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP60000744A
Other languages
English (en)
Japanese (ja)
Other versions
JPS60158197A (ja
Inventor
Rauri Antero Marubora Marutsuchi
Beitsuko Marutsuchira Esuko
Antero Uochira Yaatsuko
Kyutsuritsuki Pitsupuri Aino
Yuhani Kairisaro Petsuka
Yuhani Honkanen Erutsuki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Orion Oyj
Original Assignee
Orion Yhtyma Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion Yhtyma Oy filed Critical Orion Yhtyma Oy
Publication of JPS60158197A publication Critical patent/JPS60158197A/ja
Publication of JPH029040B2 publication Critical patent/JPH029040B2/ja
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Coloring (AREA)
JP60000744A 1984-01-06 1985-01-07 抗生物質およびその製法 Granted JPS60158197A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK58/84 1984-01-06
DK5884A DK149776C (da) 1984-01-06 1984-01-06 Antibiotisk virksom erytromycinforbindelse og praeparat indeholdende forbindelsen

Publications (2)

Publication Number Publication Date
JPS60158197A JPS60158197A (ja) 1985-08-19
JPH029040B2 true JPH029040B2 (enExample) 1990-02-28

Family

ID=8089251

Family Applications (1)

Application Number Title Priority Date Filing Date
JP60000744A Granted JPS60158197A (ja) 1984-01-06 1985-01-07 抗生物質およびその製法

Country Status (38)

Country Link
US (1) US4599326A (enExample)
JP (1) JPS60158197A (enExample)
KR (1) KR900006237B1 (enExample)
AT (1) AT386414B (enExample)
AU (1) AU565688B2 (enExample)
BE (1) BE901411A (enExample)
BG (1) BG43189A3 (enExample)
CA (1) CA1224461A (enExample)
CH (1) CH666275A5 (enExample)
CS (1) CS247191B2 (enExample)
CY (1) CY1462A (enExample)
DE (1) DE3500179A1 (enExample)
DK (1) DK149776C (enExample)
ES (1) ES8605818A1 (enExample)
FI (1) FI77249C (enExample)
FR (1) FR2557878B1 (enExample)
GB (1) GB2152502B (enExample)
HK (1) HK11590A (enExample)
HU (1) HU196221B (enExample)
IE (1) IE57967B1 (enExample)
IL (1) IL73885A (enExample)
IS (1) IS2968A7 (enExample)
IT (1) IT1184304B (enExample)
KE (1) KE3841A (enExample)
LU (1) LU85721A1 (enExample)
MA (1) MA20316A1 (enExample)
MX (1) MX156277A (enExample)
NL (1) NL8403979A (enExample)
NO (1) NO160263C (enExample)
NZ (1) NZ210606A (enExample)
PH (1) PH22471A (enExample)
PL (1) PL144349B1 (enExample)
PT (1) PT79777B (enExample)
RO (1) RO91262B (enExample)
SE (1) SE461854B (enExample)
SU (1) SU1410866A3 (enExample)
YU (1) YU44485B (enExample)
ZA (1) ZA8410143B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4874614A (en) * 1985-03-25 1989-10-17 Abbott Laboratories Pharmaceutical tableting method
US4863741A (en) * 1985-03-25 1989-09-05 Abbott Laboratories Tablet composition for drug combinations
JP3382159B2 (ja) * 1998-08-05 2003-03-04 株式会社東芝 情報記録媒体とその再生方法及び記録方法
US10004729B2 (en) 2002-07-05 2018-06-26 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
US8840928B2 (en) 2002-07-05 2014-09-23 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
US7399488B2 (en) * 2002-07-05 2008-07-15 Collegium Pharmaceutical, Inc. Abuse-deterrent pharmaceutical compositions of opiods and other drugs
CA2543945A1 (en) * 2003-10-31 2005-05-12 Alza Corporation Compositions and dosage forms for enhanced absorption of 3-amino-n-butyl-phosphinic acid
EP3326617A1 (en) 2004-06-12 2018-05-30 Collegium Pharmaceutical, Inc. Abuse-deterrent drug formulations
EP2457580A1 (en) 2004-08-25 2012-05-30 The UAB Research Foundation Absorption enhancers for drug administration
US9895444B2 (en) 2004-08-25 2018-02-20 Aegis Therapeutics, Llc Compositions for drug administration
CA2714867A1 (en) 2006-06-23 2007-12-27 Candace B. Pert Non-aggregated pharmaceutically active peptide
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
KR102512178B1 (ko) 2011-05-18 2023-03-20 메더리스 다이어비티즈, 엘엘씨 개선된 펩티드 제약
AU2013347975B2 (en) 2012-11-20 2018-07-26 Mederis Diabetes, Llc Improved peptide pharmaceuticals for insulin resistance
CA2891929C (en) 2012-11-20 2022-07-19 Eumederis Pharmaceuticals, Inc. Improved peptide pharmaceuticals
WO2014140699A1 (en) * 2013-03-13 2014-09-18 Calyx Chemicals And Pharmaceuticals Ltd A novel process of liberation of erythromycin and preparation of its salts
EP4397374A3 (en) 2014-05-28 2024-10-16 Mederis Diabetes, LLC Improved peptide pharmaceuticals for insulin resistance
WO2017222575A1 (en) 2016-06-23 2017-12-28 Collegium Pharmaceutical, Inc. Process of making more stable abuse-deterrent oral formulations
RU2019142102A (ru) 2017-05-19 2021-06-21 Лунелла Байотек, Инк. Антимитосцины: направленные ингибиторы митохондриального биогенеза для эрадикации злокачественных стволовых клеток
US11497759B2 (en) 2017-12-01 2022-11-15 Lunella Biotech, Inc. Repurposcins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cells
EP4483958A3 (en) 2018-02-06 2025-03-05 Aegis Therapeutics, LLC Intranasal epinephrine formulations and methods for the treatment of disease
JP6941224B2 (ja) 2018-02-06 2021-09-29 イージス セラピューティクス，エルエルシー 疾患の処置のための鼻腔内エピネフリン製剤及び方法
KR20210104830A (ko) * 2018-12-17 2021-08-25 루넬라 바이오테크 인코포레이티드 항노화를 위한 삼중 조합 요법
BR112021011963A2 (pt) * 2018-12-17 2021-09-08 Lunella Biotech, Inc. Terapias de combinação tripla para alvejamento de mitocôndria e exterminação de células-tronco de câncer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1011117B (de) * 1953-11-16 1957-06-27 Abbott Lab Verfahren zur Herstellung von reinen stabilen Erythromycin-Saeure-Additionssalzen
FR1179208A (fr) * 1953-11-16 1959-05-21 Abbott Lab Procédé de préparation de sels d'érythromycine
GB834397A (en) * 1958-07-29 1960-05-04 Lilly Co Eli Therapeutic compositions comprising erythromycin esters
US4150220A (en) * 1977-02-04 1979-04-17 Pfizer Inc. Semi-synthetic 4"-erythromycin A derivatives
FR2473525A1 (fr) * 1980-01-11 1981-07-17 Roussel Uclaf Nouvelles oximes derivees de l'erythromycine, leur procede de preparation et leur application comme medicaments

Also Published As

Publication number Publication date
PT79777B (en) 1986-10-21
DK5884D0 (da) 1984-01-06
MA20316A1 (fr) 1985-10-01
PT79777A (en) 1985-01-01
IE850022L (en) 1985-07-06
JPS60158197A (ja) 1985-08-19
HU196221B (en) 1988-10-28
SE8406671D0 (sv) 1984-12-28
IS2968A7 (is) 1985-04-03
HUT37628A (en) 1986-01-23
PL251457A1 (en) 1985-11-05
FI850023A0 (fi) 1985-01-03
FI77249C (fi) 1989-02-10
SE461854B (sv) 1990-04-02
PL144349B1 (en) 1988-05-31
FI850023L (fi) 1985-07-07
CY1462A (en) 1989-07-21
IE57967B1 (en) 1993-06-02
DE3500179A1 (de) 1985-07-18
RO91262A (ro) 1987-06-30
IT1184304B (it) 1987-10-28
GB8432368D0 (en) 1985-02-06
DK149776C (da) 1987-04-21
PH22471A (en) 1988-09-12
CH666275A5 (de) 1988-07-15
ZA8410143B (en) 1985-08-28
NZ210606A (en) 1987-08-31
ES8605818A1 (es) 1986-04-01
DK149776B (da) 1986-09-29
YU44485B (en) 1990-08-31
KE3841A (en) 1989-04-07
CA1224461A (en) 1987-07-21
AU565688B2 (en) 1987-09-24
KR900006237B1 (ko) 1990-08-27
DK5884A (da) 1985-07-07
LU85721A1 (fr) 1985-07-24
IT8519012A0 (it) 1985-01-04
NO850007L (no) 1985-07-08
ES539349A0 (es) 1986-04-01
FI77249B (fi) 1988-10-31
NL8403979A (nl) 1985-08-01
CS247191B2 (en) 1986-12-18
BG43189A3 (en) 1988-04-15
ATA985A (de) 1988-01-15
YU2085A (en) 1987-12-31
SE8406671L (sv) 1985-07-07
AT386414B (de) 1988-08-25
GB2152502B (en) 1987-10-07
HK11590A (en) 1990-02-23
RO91262B (ro) 1987-07-01
IL73885A0 (en) 1985-03-31
FR2557878A1 (fr) 1985-07-12
US4599326A (en) 1986-07-08
GB2152502A (en) 1985-08-07
AU3705984A (en) 1985-07-11
MX156277A (es) 1988-08-04
KR850005452A (ko) 1985-08-26
IL73885A (en) 1988-10-31
NO160263B (no) 1988-12-19
DE3500179C2 (enExample) 1989-08-24
NO160263C (no) 1989-03-29
SU1410866A3 (ru) 1988-07-15
FR2557878B1 (fr) 1988-01-15
BE901411A (fr) 1985-04-16

Similar Documents

Publication Publication Date Title
JPH029040B2 (enExample)
DK175544B1 (da) Anvendelse af azithromycin og derivater deraf til fremstilling af antiprotozoale lægemidler
EP1421093B1 (en) Crystaline clindamycin free base
JPS63258841A (ja) チロシン誘導体及びその用途
WO1988005656A1 (en) Anhydrous, crystalline sodium salt of 5-chloro-3-(2-thenoyl)-2-oxindole-1-carboxamide
KR100273937B1 (ko) 4,13-디옥사바이사이클로[8.2.1]트리데세논 유도체와 그의 제조방법 및 이 화합물이 함유된 약학조성물
US4442101A (en) Sesquihydrate of naphthyridine derivative, and process for the preparation thereof
JPH0548234B2 (enExample)
JPH0645543B2 (ja) 魚病の予防，治療剤
JPS604189B2 (ja) 抗菌剤およびその製法
US3000874A (en) Sulfate salt of erythromycin monoester
HU198440B (en) Process for producing stabil christalline sodium-acetyl-salicilate
JP3507521B2 (ja) 関節リュウマチ剤
JPS6234038B2 (enExample)
JP2520385B2 (ja) ３―置換基―７―置換したアミノ基セファロスポラナシ酸誘導体のアルカリ金属塩の製造法
JPS6121238B2 (enExample)
CA2052637A1 (en) Pharmaceutical preparation having an improved absorption property
MXPA97002824A (en) ou. PHARMACEUTICAL PREPARATIONS OF DERIVATIVES OF MACROLIDICOS DE SEGUNDA GENERAC ANTIBIOTICS
JPS60163896A (ja) 胆汁酸誘導体